Novel Nanobody Drug Conjugate as a Prophylactic or Therapeutic against SARS-CoV-2 infection in mice
Biochemical and Biophysical Research Communications,
Год журнала:
2025,
Номер
753, С. 151480 - 151480
Опубликована: Фев. 14, 2025
Язык: Английский
Efficient Sequential Chromatographic Purification of a Recombinant Nanobody-Fc Fusion Designed for Treatment of Severe Fever with Thrombocytopenia Syndrome
Annals of Advances in Chemistry,
Год журнала:
2025,
Номер
9(1), С. 001 - 006
Опубликована: Янв. 29, 2025
Severe
fever
with
thrombocytopenia
syndrome
(SFTS)
is
caused
by
a
virus
that
induces
acute
infections.
Despite
its
expansion
beyond
China,
where
it
first
appeared
in
2009,
no
specific
drug
exists
to
treat
the
disease.
The
discovery
antibodies
targeting
SFTS
surface
glycoprotein
(Glycoprotein
N,
GN)
significantly
enhance
patient
survival
has
driven
development
of
antibodies,
particularly
nanobodies.
Nanobodies
GN
protein
are
promising
therapeutic
approach.
This
paper
presents
systematic
study
purification
process
for
recombinant
nanobody-Fc
fusion
designed
HB29.
evaluated
sequential
approach
using
affinity
(AFF),
ion
exchange
(IEC),
and
hydrophobic
interaction
chromatography
(HIC)
techniques
gradually
remove
impurities.
results
demonstrate
this
achieves
an
overall
yield
more
than
50%
total
purity
95%.
Efficient
nanobody
methods,
as
outlined
here,
can
pave
way
novel
treatments
manage
Язык: Английский
The Use of Heterologous Antigens for Biopanning Enables the Selection of Broadly Neutralizing Nanobodies Against SARS-CoV-2
Antibodies,
Год журнала:
2025,
Номер
14(1), С. 23 - 23
Опубликована: Март 7, 2025
Background:
Since
the
emergence
of
SARS-CoV-2
in
human
population,
virus
genome
has
undergone
numerous
mutations,
enabling
it
to
enhance
transmissibility
and
evade
acquired
immunity.
As
a
result
these
most
monoclonal
neutralizing
antibodies
have
lost
their
efficacy,
as
they
are
unable
neutralize
new
variants.
Antibodies
that
broad
range
variants
significant
value
combating
both
current
potential
future
variants,
making
identification
development
such
an
ongoing
critical
goal.
This
study
discusses
strategy
using
heterologous
antigens
biopanning
rounds.
Methods:
After
four
rounds
biopanning,
nanobody
were
selected
from
phage
display
library.
Immunochemical
methods
used
evaluate
specificity
S
protein
various
well
determine
competitive
ability
against
ACE2.
Viral
neutralization
activity
was
analyzed.
A
three-dimensional
model
interaction
with
RBD
constructed.
Results:
Four
nanobodies
obtained
specifically
bind
receptor-binding
domain
(RBD)
spike
glycoprotein
exhibit
strains.
Conclusions:
The
demonstrates
performing
several
allows
selection
reactivity
spectrum.
However,
fourth
round
does
not
lead
improved
characteristics.
Язык: Английский
Structural Virology: The Key Determinants in Development of Antiviral Therapeutics
Viruses,
Год журнала:
2025,
Номер
17(3), С. 417 - 417
Опубликована: Март 14, 2025
Structural
virology
has
emerged
as
the
foundation
for
development
of
effective
antiviral
therapeutics.
It
is
pivotal
in
providing
crucial
insights
into
three-dimensional
frame
viruses
and
viral
proteins
at
atomic-level
or
near-atomic-level
resolution.
Structure-based
assessment
components,
including
capsids,
envelope
proteins,
replication
machinery,
host
interaction
interfaces,
instrumental
unraveling
multiplex
mechanisms
infection,
replication,
pathogenesis.
The
structural
elucidation
enzymes,
proteases,
polymerases,
integrases,
been
essential
combating
like
HIV-1
HIV-2,
SARS-CoV-2,
influenza.
Techniques
X-ray
crystallography,
Nuclear
Magnetic
Resonance
spectroscopy,
Cryo-electron
Microscopy,
Tomography
have
revolutionized
field
significantly
aided
discovery
ubiquity
chronic
infections,
along
with
emergence
reemergence
new
threats
necessitate
novel
strategies
agents,
while
extensive
diversity
their
high
mutation
rates
further
underscore
critical
need
analysis
to
aid
development.
This
review
highlights
significance
structure-based
investigations
bridging
gap
between
structure
function,
thus
facilitating
therapeutics,
vaccines,
antibodies
tackling
emerging
threats.
Язык: Английский
Challenges and design of nanobodies against arboviruses
Trends in biotechnology,
Год журнала:
2025,
Номер
unknown
Опубликована: Март 1, 2025
Язык: Английский
Nanoscale warriors against viral invaders: a comprehensive review of Nanobodies as potential antiviral therapeutics
mAbs,
Год журнала:
2025,
Номер
17(1)
Опубликована: Апрель 9, 2025
Viral
infections
remain
a
significant
global
health
threat,
with
emerging
and
reemerging
viruses
causing
epidemics
pandemics.
Despite
advancements
in
antiviral
therapies,
the
development
of
effective
treatments
is
often
hindered
by
challenges,
such
as
viral
resistance
emergence
new
strains.
In
this
context,
novel
therapeutic
modalities
essential
to
combat
notorious
viruses.
While
traditional
monoclonal
antibodies
are
widely
used
for
treatment
several
diseases,
nanobodies
derived
from
heavy
chain-only
have
emerged
promising
"nanoscale
warriors"
against
infections.
Nanobodies
possess
unique
structural
properties
that
enhance
their
ability
recognize
diverse
epitopes.
Their
small
size
also
imparts
properties,
improved
bioavailability,
solubility,
stability,
proteolytic
resistance,
making
them
an
ideal
class
therapeutics
review,
we
discuss
role
antivirals
various
Techniques
developing
nanobodies,
delivery
strategies
covered,
challenges
opportunities
associated
use
therapies
discussed.
We
offer
insights
into
future
nanobody-based
research
support
managing
Язык: Английский